MCK Stock Recent News

Besides Wall Street's top -and-bottom-line estimates for McKesson (MCK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) closed at $712.79 in the latest trading session, marking a +0.78% move from the prior day.

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.

McKesson (MCK) reachead $699.73 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.

McKesson (MCK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

MCK moves higher through the session after Alert

In the latest trading session, McKesson (MCK) closed at $695.17, marking a +1.86% move from the previous day.

In the most recent trading session, McKesson (MCK) closed at $694.70, indicating a +0.27% shift from the previous trading day.

IRVING, Texas--(BUSINESS WIRE)--McKesson launched an initiative addressing the clinical challenges and administrative burden practices face in the era of biomarker-directed care.